Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Axel Ursenbach; Yvon Ruch; Baptiste Hoellinger; Anne Fuchs; Stephanie Caspar; Frederick Jegou; David Rey; Samira Fafi-Kremer; Thibault Mesplede; Pierre Gantner

doi:10.1093/cid/ciae006

Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Axel Ursenbach
, Yvon Ruch
, Baptiste Hoellinger
, Anne Fuchs
, Stephanie Caspar
, Frederick Jegou
, David Rey
, Samira Fafi-Kremer
, Thibault Mesplede
, Pierre Gantner

Virology

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

9 Downloads (Pure)

Abstract

Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.

Original language	English
Article number	ciae006
Pages (from-to)	198-201
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	79
Issue number	1
Early online date	9 Jan 2024
DOIs	https://doi.org/10.1093/cid/ciae006
Publication status	Published - 15 Jul 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/cid/ciae006

ciae006Final published version, 403 KBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{39c48b7b324f43c0905748fdc88fe7ee,

title = "Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification",

abstract = "Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.",

author = "Axel Ursenbach and Yvon Ruch and Baptiste Hoellinger and Anne Fuchs and Stephanie Caspar and Frederick Jegou and David Rey and Samira Fafi-Kremer and Thibault Mesplede and Pierre Gantner",

year = "2024",

month = jul,

day = "15",

doi = "10.1093/cid/ciae006",

language = "English",

volume = "79",

pages = "198--201",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

AU - Ursenbach, Axel

AU - Ruch, Yvon

AU - Hoellinger, Baptiste

AU - Fuchs, Anne

AU - Caspar, Stephanie

AU - Jegou, Frederick

AU - Rey, David

AU - Fafi-Kremer, Samira

AU - Mesplede, Thibault

AU - Gantner, Pierre

PY - 2024/7/15

Y1 - 2024/7/15

N2 - Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.

AB - Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:001145590200001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1093/cid/ciae006

DO - 10.1093/cid/ciae006

M3 - Article

C2 - 38193816

SN - 1058-4838

VL - 79

SP - 198

EP - 201

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

M1 - ciae006

ER -

Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this